Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SGN 35C

Next Previous
Drug Profile

SGN 35C

Alternative Names: 35C; PF-08046044; SGN-35C

Latest Information Update: 25 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seagen
  • Class Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunotoxins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma

Most Recent Events

  • 13 Apr 2026 Seagen terminates phase-I clinical trials in Lymphoma (Late-stage disease, Second-line therapy or greater, Monotherapy) in USA, Spain, United Kingdom, Italy, France, Denmark (IV) due to portfolio reprioritization (NCT06254495) (CTIS2023-505813-26-00)
  • 06 Dec 2025 Pharmacodynamics, efficacy, adverse events, pharmacokinetics data from a phase I trial in Lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 12 Feb 2024 Seagen plans a phase I trial for Cancer (Late-stage disease, Second-line therapy or greater) (IV) in May 2024 (NCT06254495)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top